BlackRock Inc. increased its holdings in shares of Moleculin Biotech Inc (NASDAQ:MBRX) by 134.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 112,572 shares of the company’s stock after purchasing an additional 64,632 shares during the quarter. BlackRock Inc. owned approximately 0.25% of Moleculin Biotech worth $141,000 at the end of the most recent quarter.
Separately, Renaissance Technologies LLC lifted its stake in Moleculin Biotech by 430.4% during the second quarter. Renaissance Technologies LLC now owns 833,664 shares of the company’s stock worth $1,042,000 after purchasing an additional 676,500 shares during the last quarter. 9.41% of the stock is owned by institutional investors.
Several equities research analysts recently weighed in on MBRX shares. Maxim Group set a $3.00 target price on Moleculin Biotech and gave the stock a “buy” rating in a research note on Tuesday, August 20th. Oppenheimer started coverage on Moleculin Biotech in a research note on Thursday, October 17th. They set an “outperform” rating and a $2.00 target price for the company. Finally, ValuEngine cut Moleculin Biotech from a “buy” rating to a “hold” rating in a research note on Wednesday. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $4.33.
MBRX opened at $1.07 on Friday. The firm has a market cap of $49.72 million, a price-to-earnings ratio of -2.10 and a beta of 1.96. Moleculin Biotech Inc has a 52 week low of $0.78 and a 52 week high of $3.15. The business’s 50 day moving average is $1.10 and its two-hundred day moving average is $1.17. The company has a quick ratio of 2.11, a current ratio of 2.11 and a debt-to-equity ratio of 0.01.
Moleculin Biotech (NASDAQ:MBRX) last released its quarterly earnings results on Friday, August 16th. The company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.07. Equities analysts expect that Moleculin Biotech Inc will post -0.4 EPS for the current fiscal year.
About Moleculin Biotech
Moleculin Biotech, Inc, a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company also develops WP1066 Portfolio, an immuno-stimulating STAT3 inhibitor for the treatment of brain tumors, pancreatic cancer, and AML; and WP1122 Portfolio and related molecules for the treatment of glioblastoma multiforme and related central nervous system malignancies.
Receive News & Ratings for Moleculin Biotech Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Moleculin Biotech and related companies with MarketBeat.com’s FREE daily email newsletter.